GlassScriptPhysician profile
Ramnik Joseph Xavier
NPI 1275523359
$567,357.96
in general payments reported to CMS, 2019-2025
5 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2023: $154 · 2024: $440K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $529K · Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $528,610.14 |
| Food and Beverage | $154.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528,610.14 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $38,593.76 | 2019 | |
| Glaxosmithkline, LLC. | $154.06 | 2023 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramnik Xavier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.